{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+film&page=4",
    "query": {
      "intervention": "Placebo film",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 309,
    "total_pages": 31,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+film&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+film&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-07T22:31:52.446Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03787004",
      "title": "A Placebo-Controlled, Two-Part Study, Oral Dose to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of CNTX-6970 in Healthy Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Pain",
        "Nociceptive Pain"
      ],
      "interventions": [
        {
          "name": "CNTX-6970",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Centrexion Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 62,
      "start_date": "2017-08-14",
      "completion_date": "2018-09-26",
      "has_results": false,
      "last_update_posted_date": "2018-12-26",
      "last_synced_at": "2026-10-07T22:31:52.446Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03787004"
    },
    {
      "nct_id": "NCT03939364",
      "title": "This Study is to Evaluate the Safety and Pharmacokinetics of SBS-101 in Patients With Oral Premalignant Lesions",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukoplakia, Oral"
      ],
      "interventions": [
        {
          "name": "SBS-101",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Skyline Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-01",
      "completion_date": "2023-05",
      "has_results": false,
      "last_update_posted_date": "2021-10-19",
      "last_synced_at": "2026-10-07T22:31:52.446Z",
      "location_count": 5,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • Charlotte, North Carolina + 2 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03939364"
    },
    {
      "nct_id": "NCT03338998",
      "title": "Efficacy, Safety and Tolerability of BAF312 Compared to Placebo in Patients With Intracerebral Hemorrhage (ICH).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hemorrhagic Stroke",
        "Intracerebral Hemorrhage (ICH)"
      ],
      "interventions": [
        {
          "name": "BAF312 solution",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo for BAF312 solution",
          "type": "DRUG"
        },
        {
          "name": "BAF312 tablet",
          "type": "DRUG"
        },
        {
          "name": "Matching Placebo for BAF312 tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 32,
      "start_date": "2017-12-24",
      "completion_date": "2020-05-13",
      "has_results": true,
      "last_update_posted_date": "2022-08-12",
      "last_synced_at": "2026-10-07T22:31:52.446Z",
      "location_count": 11,
      "location_summary": "Palo Alto, California • New Haven, Connecticut • Atlanta, Georgia + 7 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03338998"
    },
    {
      "nct_id": "NCT00134563",
      "title": "Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for teriflunomide)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1088,
      "start_date": "2004-09",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2013-01-04",
      "last_synced_at": "2026-10-07T22:31:52.446Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00134563"
    },
    {
      "nct_id": "NCT01170962",
      "title": "Study of the Anti-HCV Drug (BMS-790052) Combined With Peginterferon and Ribavirin in Patients Who Failed Prior Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus"
      ],
      "interventions": [
        {
          "name": "BMS-790052",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "peginterferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 512,
      "start_date": "2010-08",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2015-10-12",
      "last_synced_at": "2026-10-07T22:31:52.446Z",
      "location_count": 35,
      "location_summary": "Montgomery, Alabama • La Jolla, California • Los Angeles, California + 28 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01170962"
    },
    {
      "nct_id": "NCT00902174",
      "title": "Imatinib (QTI571) in Pulmonary Arterial Hypertension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Arterial Hypertension"
      ],
      "interventions": [
        {
          "name": "imatinib mesylate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 202,
      "start_date": "2009-09",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2016-02-17",
      "last_synced_at": "2026-10-07T22:31:52.446Z",
      "location_count": 33,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00902174"
    },
    {
      "nct_id": "NCT03429543",
      "title": "Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Insulin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Linagliptin",
          "type": "DRUG"
        },
        {
          "name": "Empagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 175,
      "start_date": "2018-03-20",
      "completion_date": "2023-05-31",
      "has_results": true,
      "last_update_posted_date": "2024-02-23",
      "last_synced_at": "2026-10-07T22:31:52.446Z",
      "location_count": 44,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Orange, California + 39 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03429543"
    },
    {
      "nct_id": "NCT00489489",
      "title": "Phase II Study of Teriflunomide as Adjunctive Therapy to Interferon-beta in Subjects With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for Teriflunomide)",
          "type": "DRUG"
        },
        {
          "name": "Interferon-β",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 118,
      "start_date": "2007-05",
      "completion_date": "2009-06",
      "has_results": true,
      "last_update_posted_date": "2012-11-06",
      "last_synced_at": "2026-10-07T22:31:52.446Z",
      "location_count": 1,
      "location_summary": "Bridgewater, New Jersey",
      "locations": [
        {
          "city": "Bridgewater",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00489489"
    },
    {
      "nct_id": "NCT03324581",
      "title": "The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Attention Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "OPC-64005",
          "type": "DRUG"
        },
        {
          "name": "Atomoxetine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 239,
      "start_date": "2017-11-09",
      "completion_date": "2018-10-31",
      "has_results": true,
      "last_update_posted_date": "2021-10-29",
      "last_synced_at": "2026-10-07T22:31:52.446Z",
      "location_count": 26,
      "location_summary": "Beverly Hills, California • Garden Grove, California • San Diego, California + 20 more",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Garden Grove",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Marcos",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03324581"
    },
    {
      "nct_id": "NCT02783573",
      "title": "A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "Lanabecestat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 1722,
      "start_date": "2016-07-01",
      "completion_date": "2018-09-28",
      "has_results": true,
      "last_update_posted_date": "2019-12-03",
      "last_synced_at": "2026-10-07T22:31:52.446Z",
      "location_count": 90,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 73 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02783573"
    }
  ]
}